InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,304.80
(
0.47%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.52
(
0.12%
)
Bitcoin
61,894.29
(
0.46%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: rfj1862 post# 222187

Monday, 11/12/2018 6:00:25 PM

Monday, November 12, 2018 6:00:25 PM

Post# of 252412
PARPi would fall into my proven drug category. Still, it is theoretical not proven in clinic. Data from several PARPi in combination with anti-PD1 had been presented, it is mixed but interesting nevertheless. It wasn’t as apparent as anti-PD1 in combination with chemo/TKI based on earlier data. It might take time to work or find right indications and settings etc, but definitely worth of exploring further. MRK deal with AZN on PARPi probably was a lower risk bet on PARPi beyond monotherapy alone.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up